Liver Diseases  >>  aldafermin (NGM282)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
aldafermin (NGM282) / NGM Biopharma
NCT02135536: Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis

Completed
2b
36
US, RoW
NGM282
NGM Biopharmaceuticals, Inc, NGM Biopharmaceuticals Australia Pty Ltd
Primary Biliary Cirrhosis
02/16
02/16
NCT02026401: Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

Completed
2
45
US, RoW
NGM282, Placebo
NGM Biopharmaceuticals, Inc, NGM Biopharmaceuticals Australia Pty Ltd
Primary Biliary Cirrhosis
12/14
12/14

Download Options